In this case, the patient was treated with ascorbic acid, an antioxidant that aids in the reduction of methemoglobin to hemoglobin without inducing hemolysis, showcasing an effective management strategy for this complex condition [18]. The use of ascorbic acid versus methylene blue underscores the need for alternative therapeutic strategies in patients with G6PD deficiency and methemoglobinemia. The gene discussed is HBG2; the disease is methemoglobinemia.